Laekna and Eli Lilly to develop ActRIIA antibody for muscle-preserving weight loss in obesity
Laekna Therapeutics has entered a clinical collaboration with Eli Lilly to accelerate the development of LAE102, a novel Activin Receptor...
top of page
Browse by category
Search
Biophytis obtains IND approval to start its phase 2 OBA study in obesity
Biophytis has received Investigational New Drug (IND) approval from the FDA for its phase 2 OBA clinical study in obesity with BIO101...
Browse by tag
bottom of page